Tag: stage

July 28, 2025
News Release

SANTA ANA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the presentation of a poster entitled, “Mechanism of Action of Troculeucel (Non-genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) in Alzheimer's Disease Confirmed by Corresponding Phase I Biomarker Data” at the Alzheimer’s Association International Conference 2025 (“AAIC 2025”) held in Toronto, Canada and online from July 27-31, 2025.

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing gene expression for improved lipid clearance. Arimoclomol for the treatment of NPC has been designated as an Orphan Medicinal Product by the EMA. Arimoclomol is marketed in the U.S. under the brand name MIPLYFFA®.

LUXEMBOURG, July 26, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift (BTC3), a next-generation blockchain infrastructure protocol, is approaching the final hours of Stage 1 of its presale, offering early adopters programmable Proof-of-Yield (PoY) rewards and ecosystem access at a fixed entry price of $1.00. The project has drawn attention for launching with built-in staking incentives, AI-driven governance, and a collateral-backed stablecoin—all live from day one.

LUXEMBOURG, July 26, 2025 (GLOBE NEWSWIRE) -- As investor focus shifts away from large-cap cryptocurrencies with limited upside, early-stage projects with real-world utility and scalable technology are gaining traction. One such project is Bitcoin Swift (BTC3), a next-generation blockchain protocol currently in its presale phase. With a fixed price of $1.00 during Stage 1 and a confirmed $15.00 launch target, Bitcoin Swift is positioning itself as a notable entry in the 2025 crypto landscape.